SEDLine Announces Acquisition of Hospira Brain Function Monitoring Business
SEDLine™, Inc., announced today that it has acquired the brain function monitoring business of Hospira, Inc. (
Brain function monitoring (BFM) has become a widely utilized modality for assessing depth of anesthesia and sedation. Based primarily on analysis of the electroencephalogram (EEG), brain function monitors continuously measure the electrical activity of the brain and translate those changes to the level of consciousness. BFM has been deployed in a variety of clinical environments, ranging from the operating room for patients having surgery, to intensive care units where critically ill patients can be sedated for prolonged periods, and in short procedure units where patients undergo procedures such as colonoscopy and endoscopy.
SEDLine’s technology is based on 10 years of innovation and offers a cost-effective alternative to other monitors, while delivering proven 4-channel EEG integrated algorithm performance, demonstrated reliability under challenging clinical conditions and superior resistance to cautery1.
David E. Goodman, MD, MSE, President & CEO, SEDLine commented, “We are very excited to acquire the SEDLine brain function monitoring platform from Hospira. We intend to continue Hospira’s tradition of providing outstanding support for its customers. To reinforce our commitment to the newly acquired product line, the original Hospira Brain Function Monitoring team has joined SEDLine, Inc., ensuring that we will be able to provide all of the products, service, and support previously received from Hospira.”
Joe E. Kiani, Founder, Chairman and CEO of Masimo Corporation, commented, “We are happy to be able to provide an investment in SEDLine to help it advance and improve brain function monitoring for patients under anesthesia and sedation. Their clear commitment to invest in R&D as well as to offer excellent customer care resonates well with Masimo, and we wish them great success as they launch their new company.”
Financial details of the agreement were not disclosed.
SEDLine, Inc. is a research-focused company with the mission to expand the scope and applications for neuromonitoring. Based on over 10 years of technical and clinical development, the SEDLine core product is a pioneering four-channel brain-function monitor that measures the effects of anesthesia and sedation by simultaneously analyzing, quantifying and displaying both sides of the brain’s electrical activity. The SEDLine monitor is currently in use at some of the nation’s leading healthcare institutions. Privately held and based in Irvine, California, SEDLine has an active R&D effort underway to develop advanced brain function monitoring technologies for next generation monitors to further improve the care of patients under anesthesia or sedation. Additional information about SEDLine may be found at www.sedline.com.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.